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Abstract
Background: To identify the prevalence and clinical outcomes of pT0 disease following neoadjuvant hormonal
therapy (NHT) and radical prostatectomy (RP) in high-risk prostate cancer.
Methods: We retrospectively included 111 patients who had received NHT and RP for the treatment of high-risk
prostate cancer. We classified the patients into two groups, the pT0 group and the non-pT0 group, depending on
whether a residual tumor was observed.
Results: We identified 6 cases (5.4 %) with pT0 disease after reviewing the slides of all patients. There was no
recurrence of disease in the pT0 group during a median follow-up of 59 months. Among the 105 patients in the
non-pT0 group, biochemical recurrence (BCR) developed in 60 patients (57.1 %), with the median time to BCR
being 14 months.
Conclusions: Among the 111 patients with high-risk prostate cancer, we found 6 cases that showed a complete
pathological response after NHT and no recurrence of disease during the follow-up, meaning that the androgen
deprivation therapy could potentially eradicate high-risk prostate cancer. This is one of the largest studies
demonstrating the prevalence of pT0 disease and its outcomes after NHT among patients with high-risk prostate
cancer.
Background
pT0 prostate cancer, also known as no residual tumor,
undetectable tumor, or vanishing tumor, is not common in
biopsy-proven cases of prostate cancer. In patients who
have not received androgen deprivation therapy (ADT)
prior to radical prostatectomy (RP), the incidence of pT0
disease is reported to be between 0.07 and 0.5 % [1, 2]. In
reality, it is difficult for the surgeon to explain the final
diagnosis of pT0 disease to patients, due to their concerns
regarding unnecessary surgery for insignificant disease.
Conversely, in patients with advanced stage disease
such as high-risk disease or locally advanced disease,
we suggest that a diagnosis of pT0 following ADT could
indicate a complete pathological response or complete
tumor eradication after neoadjuvant hormonal therapy
(NHT). pT0 disease is more common in patients who
have received ADT, and has a wider prevalence than in
patients who have not received ADT.
To date, the use of ADT prior to RP has been explored
in multiple studies [3]. However, the use of ADT in a neo-
adjuvant setting prior to RP is not currently recommended
due to the absence of clear evidence of a survival benefit of
ADT for localized prostate cancer. Considering only high-
risk disease or locally advanced disease, ADT followed by
RP achieves long-term progression-free survival (PFS) and
overall survival (OS) comparable to alternative strategies
such as combined radiation therapy (RT) and ADT [4, 5].
At our institution, we perform ADT prior to RP in
patients with locally advanced prostate cancer or high-risk
disease at the surgeon’s discretion. Notably, we have expe-
rienced pT0 disease following NHT and RP among these
patients. We designed this study to confirm our hypoth-
esis that pT0 disease following NHT and RP could show
outstanding clinical outcomes in patients with high-risk
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disease. There exist rare reports in the literature that dem-
onstrate the occurrence of pT0 disease in high-risk pros-
tate cancer through subgroup analysis in a small number
of patients [6, 7]. Here, we review our prostate cancer
database to identify the prevalence of pT0 disease among
patients with high-risk disease and the clinical outcomes
of these patients during the follow-up. To the best of our
knowledge, this is one of the largest studies to demon-
strate the prevalence of pT0 disease after NHT in more
than 100 patients belonging to the high-risk group.
Methods
Patient selection
Between May 2002 and June 2013 we retrospectively identi-
fied 120 patients who had received NHTand RP by review-
ing the Korean National Cancer Center’s prostate cancer
database, in which the clinicopathological data and clinical
outcomes were prospectively recorded. In each case, the
combination of NHT and surgery was decided at the
surgeon’s discretion. Among these 120 patients, we selected
111 patients who had high-risk prostate cancer that was
defined based on the D’Amico criteria as PSA ≥ 20 ng/ml,
biopsy Gleason score (GS) ≥8, or clinical stage ≥ cT2c for
the present study. After obtaining informed consent from
each patient, NHT and RP were performed. NHT consisted
of at least 3 months of luteinizing hormone-releasing
hormone (LHRH) agonist therapy, and radical prostatec-
tomy was performed with standard pelvic lymph node
dissection. All of the patients were followed up with serum
PSA evaluation every 3 months for the first year, biannually
from the second to the fifth year, and annually thereafter.
When biochemical recurrence (BCR) developed, radio-
logical studies such as magnetic resonance imaging, com-
puted tomography, or bone scanning were performed, if
required. When the (PSA) nadir level did not decrease
below 0.2 ng/ml following RP, adjuvant ADT or RT was
given at the physician’s discretion. Salvage RT or ADT was
recommended for the patients who experienced local
recurrence or distant metastasis.
For pathological diagnosis, all of the prostatectomy speci-
mens were processed using complete transverse sections of
the whole mounted prostatectomy specimens, from the
apex to the base at 4-mm intervals. In addition to conven-
tional hematoxylin & eosin (H&E) staining, we performed
immunohistochemical staining in all the cases using several
antibodies including PSA, PSMA, PSCA, AMACR, and
p63. For the cases that were recorded as having pT0 disease
in our database, two pathologists reviewed all the slides in
each case in order to confirm the pT0 stage. This study was
approved by the Institutional Review Board of the Korean
National Cancer Center (NCCNCS05-049). Subject’s
informed consent was obtained and documented in accord-
ance with local regulations, ICH-GCP requirements, and
the ethical principles that have their origin in the principles
of the Declaration of Helsinki.
Statistical analysis
For comparative analysis, we classified the patients into two
groups, the pT0 group and the non-pT0 group depending
on whether a residual tumor was observed. We compared
the clinicopathological characteristics between the two
groups using the Fisher’s exact test for categorical variables,
and the Wilcoxon rank-sum test for continuous variables.
BCR definition that we currently use after RP is 2 consecu-
tive values of 0.2 ng/ml or greater after surgery. Local
recurrence was defined as a newly developed lesion identi-
fied around the area of prior prostatectomy in any of the
imaging studies. Clinical outcomes of patients after treat-
ment were determined based on BCR or clinical progres-
sion, including local recurrence, distant metastasis, and
survival, by applying the Kaplan-Meier method. PFS was
defined as the time to the first evidence of biochemical,
local, or distant metastasis, or death in the absence of dis-
ease progression. Statistical significance was defined as p <
0.05. All analyses were performed using the SPSS soft-
ware package (SPSS, Inc., Chicago, version 12.0 for
Windows 2007).
Results
Among the 111 patients with high risk disease, we identi-
fied 6 cases (5.4 %) with pT0 disease in our study. After
reviewing all the slides of these 6 cases, we did not find any
apparent tumors, hence we finally confirmed the presence
of pT0 disease. Microscopic findings in the prostate tissue
after ADT included atrophy of the gland, basal cell promin-
ence, vacuolated luminal cell layers, and squamous and
transitional cell metaplasia of the non-tumor gland. The
tumor glands usually showed smaller tumors within,
pyknosis, empty glandular spaces, and vacuolization and
degeneration of tumor cells with an inflammatory re-
sponse. When pyknotic cells were positive for cytokeratin,
PSA, or AMACR on immunohistochemical staining, they
were considered to demonstrate the presence of a viable
residual tumor.
Patient characteristics of the 6 cases of pT0 disease are
presented in Table 1. Patient age was significantly different
between the pT0 and the non-pT0 groups. The 6 patients
with pT0 disease were older than the patients with non-
pT0 disease (p = 0.014). Otherwise, no significant differ-
ences were observed in the clinical features including the
baseline PSA level, biopsy GS, clinical stage, or number of
positive biopsy cores (Table 2).
Regarding the pathological stage in the non-pT0 group,
an organ-confined tumor (pT2) was found in 46 cases
(43.8 %), locally-advanced disease including pT3 and pT4
were found in 46 cases (43.8 %), and pelvic lymph node
(LN) metastasis was found in 13 cases (12.4 %). A positive
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surgical margin was observed in 28 patients (26.7 %) in
the non-pT0 group including 7 patients (15.2 %) with
stage pT2 and 15 patients (32.6 %) with stage pT3-pT4.
ADT was added as an adjuvant treatment following RP in
18 patients (17.1 %), and there was no case that received
adjuvant RT in this group. Patients in the pT0 group did
not receive any additional treatment.
At the time of analysis, the median follow-up period
was 54 months (range, 3 to 102 months) in all patients. In
the pT0 group, all patients were alive and there was no
Table 1 Characteristics of patients with pT0 prostate cancer
Patient
number




















1 66 24.6 <0.1 6 months T2cNoMo 7 6 10.0 48
2 77 55.3 0.3 3 months T3aN0M0 6 3 3.0 60
3 66 20.9 <0.1 6 months T3aN0M0 7 3 21.0 80
4 76 6.18 <0.1 3 months T2cNoMo 7 8 12.0 74
5 73 9.4 <0.1 12 months T3aN0M0 7 8 5.0 57
6 74 19.38 <0.1 6 months T3aN0M0 8 6 10.0 6
PSA prostate-specific antigen, NHT neoadjuvant hormonal therapy, GS Gleason score
Table 2 Clinicopathological features between the two groups
pT0 group (n = 6) Non-pT0 group (n = 105) P-value
Age, median (range) 73.5 (66–77) 66.0 (47–77) 0.014
PSA, median (range) 20.14 (6.18–55.30) 39.50 (4.16–261.80) 0.126
Biopsy GS (%) 0.447
2–6 1 (16.7) 19 (18.1)
7 4 (66.7) 44 (41.9)
8–10 1 (16.7) 42 (40.0)
Clinical stage (%) 0.461
cT1c- cT2b 0 (0.0) 10 (9.5)
cT2c 2 (33.3) 50 (47.6)
cT3-cT4 4 (66.7) 45 (42.9)
Median number of positive cores on biopsy (range) 6 (3–8) 6 (1–13) 0.599
Median maximum tumor length (range) 10.0 mm (3.0–21.0) 11.0 mm (0.5–25.0) 0.806
Median duration of NHT (range) 6 months (3–12) 3 months (3–30) 0.144






Positive resection margin 28 (26.7)
In pT2 7 (15.2 %)
In pT3-pT4 15 (32.6 %)
In N1 6 (46.2 %)
Seminal vesicle invasion 36 (34.3))
Prostate volume, median (range) 22.0 gm (16.0–24.1) 24.9gm (7.5–50.0) 0.280
Tumor volume, % (range) 0 20 (1–90)
PSA prostate-specific antigen, NHT neoadjuvant hormonal therapy, GS Gleason score, NA not available
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recurrence of disease during the median follow-up of
59 months (range, 6 to 80 months). Among the 105
patients in the non-pT0 group, BCR developed in 60
patients (57.1 %), and the median time to BCR was
14 months (range, 5–56 months). Clinical progression
occurred in 11 patients (10.5 %) including 9 patients
(8.6 %) with local recurrence and 9 patients (8.6 %) with
metastasis. 5-year PFS was 30.3 %, and 5-year clinical PFS
and 5-year metastasis-free survival were 86.2 and 87.2 %,
respectively. 6 patients (5.7 %) progressed to castration-
resistant prostate cancer. Death occurred in 11 patients
(10.5 %); prostate cancer-specific death in 3 cases (2.9 %)
and death due to other causes in 8 cases (7.6 %). At 5 years,
the overall survival (OS) and cancer-specific survival
(CSS) were 91.5 and 97.7 %, respectively (Fig. 1).
Discussion
In patients with high-risk prostate cancer, we observed 6
cases (5.4 %) of pT0 disease that showed no tumor re-
currence during the follow-up. Our results indicate that
ADT can induce a complete pathological response, and
can potentially eradicate advanced prostate cancer.
Regarding the issue of pT0 disease in surgical specimens,
the majority of surgeons were initially concerned about
unnecessary surgery or overtreatment in patients with no
residual tumors. The occurrence of pT0 disease has been
reported in many previous studies of prostatectomy series.
The prevalence of pT0 disease was found to be between 0.2
and 1.3 % in the prostatectomy series, and it was more
common in localized prostate cancer in the low-risk group
and in small tumors such as those with less than 2 positive
cores on biopsy [1, 8–10]. In Korean patients, the likelihood
of occurrence of pT0 disease was found to be related to the
biopsy Gleason score, the number of positive cores on
biopsy, the tumor length in a positive core, and prostate
volume [10].
pT0 disease in prostatectomy specimens is more
commonly detected in patients who receive ADT prior
to surgery. Due to the effect of androgen deprivation,
the prostate tumor shows glandular shrinkage includ-
ing pyknosis, empty glandular spaces, and vacuoliza-
tion and degeneration of tumor cells. In addition, ADT
reduces the frequency of tumor extension to surgical
margins [11].
The occurrence of pT0 disease following ADT has led to
increased clinical interest in investigating the role of ADT,
because patients with pT0 stage prostate cancer are ex-
pected to have an extremely favorable prognosis. NHT is
initially intended to improve the surgical outcomes by
minimizing the rate of positive surgical margins following
RP. Early studies assessing the efficacy of NHT demon-
strated a decrease in tumor volume and positive surgical
margin rates, and an increase in the rate of pathologically
organ-confined cancer [12, 13]. Many investigators have
assessed the effect of combined NHT and RP on the sur-
vival outcomes in patients with prostate cancer, however,
the effect of NHT adjunctive to RP has not been satisfac-
torily supported by existing evidence [3], which is different
to the results seen with ADT prior to RT [14, 15]. Several
guidelines have stated that there is no benefit to the
administration of ADT prior to RP in localized cancer,
based on the results of previous studies. Considering only
Fig. 1 Overall survival (a) and cancer-specific survival (b) between the pT0 and non-pT0 groups
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high-risk or locally advanced prostate cancer, combined
NHT and RP achieves a long-term PFS and OS compar-
able to the alternative strategy of combined RT and ADT
[4, 5]. In the current study, we also achieved good results
for the 5-year survival outcome, which was comparable to
previous reports, despite a higher BCR rate.
With respect to the prevalence of pT0 disease after ADT,
it is more common and has a wider prevalence compared
with that in non-ADT cases. In one study, 36 (20.7 %) out
of 174 patients who received NHT did not show any
residual tumor in RP specimens [6]. In another study of
high-risk disease, 2 (9.5 %) out of 21 patients did not show
any residual tumor after 8 months of ADT before RP [7].
In the current study, pT0 disease was observed in 5.4 % of
the patients with high-risk prostate cancer. This difference
in the prevalence of pT0 after ADT may be related to the
varying degree of diagnostic accuracy in detecting residual
tumors that undergo histological changes following ADT,
varying durations of ADT, and highly heterogeneous char-
acteristics of tumors in each study.
In prostate cancer, diagnosis is generally made based
on a routine pathological exam using standard processes
such as H&E staining in a limited number of slides. In
one study, after microscopic reassessment of the slides,
very small tumor remnants with a mean volume of
0.2 ml were detected in 13 of the 20 prostatectomy spec-
imens [16]. Considering our diagnostic procedure of using
whole mounted sections and reexamination by patholo-
gists who have excellent experience in the assessment of
ADT-related cases, we are confident that the pT0 stage
indicates a complete pathological response and eradica-
tion of the tumor following ADT.
The duration of ADT could also affect the incidence of
pT0 disease. Prolonged NHT results in an additional
decrease in tumor volume and positive surgical margin
rates, and an increase in the rate of pathologically-
confirmed organ-confined cancer and prevalence of pT0
disease [16, 17]. Based on the results of the current study,
we found that ADT administered for only 3 months
induced a complete pathological response in 2 patients.
The pathological response following ADT may be differ-
ent depending on the tumor characteristics of each case.
Among the prostatectomy cases that received NHT in a
previous report, 43 % of patients still showed an unaltered
area in tissues upon microscopic examination [11], indicat-
ing remarkable differences in the response of prostate
cancer to ADT. In another previous study, after stratifying
the rate of pT0 disease depending on the clinical stage (cT),
pT0 was observed in 36.7 % of patients with cT1 prostate
cancer, 33.9 % of patients with cT2 prostate cancer, and
5.9 % of patients with cT3 prostate cancer [6]. In a multi-
institutional prospective trial including Japanese patients
with high-risk disease, 8 months of ADT administration
before RP resulted in no residual tumor (pT0) in 2 out of
21 patients (9.5 %) [7]. Despite being a retrospective study
at a single institution, our present study included 111
patients with high-risk prostate cancer, of which 6 patients
(5.4 %) were finally diagnosed as having pT0 disease, mak-
ing this one of the largest data sets showing the rate of pT0
disease after NHTamong patients in the high-risk group.
Theoretically, pT0 disease is assumed to have a good
prognosis since relapse does not occur or occurs ex-
tremely rarely in pT0 patients. As expected, some studies
have not shown biochemical or clinical progression of the
disease [8, 18, 19]. However, Kollermann et al., showed
that BCR was observed in 7 (18.4 %) of 38 patients with
pT0 disease during a median follow-up of 47 months.
Among these, 3 cases showed local or systemic tumor
relapse [20]. Furthermore, PSA progression-free survival
in the pT0 group was no different to that in the non-pT0
group in a matched pair analysis [6]. In a Japanese study
of high-risk disease, BCR developed in half of the 21
patients with pT0 disease after 8 months of NHT [7].
These inconsistent results of clinical outcomes in pT0 dis-
ease are related to the diagnostic accuracy in detecting
residual tumor and the length of follow-up. In fact, we
cannot exclude the possibility that we may have experi-
enced a relapse of the disease among patients with pT0
disease in the current study if the duration of the follow-
up was longer. On the contrary, Bostwick et al., reported
that none of the 34 pT0 patients had a relapse during a
mean follow-up of 9.6 years, which is the longest follow-
up data set to date [1].
Although we obtained encouraging results that showed
no relapse of the disease, as well as the occurrence of pT0
disease in high-risk prostate cancer patients, there are some
limitations to this study due to its retrospective nature.
Firstly, we only had 6 cases of pT0 disease. Although we
analyzed some characteristics of the patients using a non-
parametric method due to the very small number of pT0
patients, we could not compare the pT0 group with the
non-pT0 group by performing a matched-pair analysis.
Secondly, the length of the follow-up period was limited.
The median follow-up duration in the pT0 group was
59 months, which is not a sufficient time period to assess
recurrence of the disease or the effect of pT0 disease on
long-term survival in other localized prostate cancer with
low or intermediate risk. Considering that BCR developed
in more than 50 % of patients in the non-pT0 group of the
current study, this follow-up duration may be sufficient to
assess the clinical outcomes in high-risk prostate cancer.
Thirdly, there was no case of tumor relapse in the pT0
group. In some reports, pT0 patients have shown frequent
recurrence of the tumor, which may be due to the prob-
able over-diagnosis of pT0 disease due to insufficient par-
tial sampling of prostatectomy specimens or missing small
foci in the tumor. As already mentioned, we are confident
that our pT0 stage indicates tumor eradication due to a
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complete pathological response to ADT, which led to
good clinical outcomes of pT0 prostate cancer.
Although there was no statistically significant difference
in the duration of ADT between the two groups, there was
a wide variation in the duration of ADT due to the retro-
spective study design. It is assumed that the duration of
NHT can affect the prevalence of pT0 disease and tumor
relapse. Further prospectively-designed studies are required
in order to refine and standardize the duration of therapy.
Conclusions
Among the 111 patients with high-risk prostate cancer
who received NHT and RP, we found 6 cases (5.4 %) that
had no apparent residual tumor, and they were diagnosed
as having pT0 disease from the prostatectomy specimens.
Of interest, we observed that none of the pT0 patients
showed disease recurrence, indicating a potential benefit of
NHT as a preoperative treatment in patients with high-risk
prostate cancer. Furthermore, NHT may have the ability to
eradicate prostate cancer. This is one of the largest studies
showing the prevalence of pT0 disease after NHT among
patients with high-risk prostate cancer.
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